suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,000
- 试验地点
- 28
- 主要终点
- The ratio of patients who will develop serious respiratory failure (SRF)
研究概览
简要总结
In the SAVE study patients with lower respiratory tract infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high risk for progression to serious respiratory failure will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in serious respiratory failure.
详细描述
The major hurdle of Coronavirus disease 2019 (COVID-19) is the early recognition of the patients at high risk for the development of severe respiratory failure (SRF). If this can be achieved early, then appropriate immunomodulatory treatment may be administered to prevent development of SRF. This scenario is extremely visionary since it prevents the development of the major fatal consequence of COVID-19 but also alleviates the heavy medical and financial burden of Intensive Care Unit (ICU) admission.
Current evidence suggests that SARS-CoV-2 activates endothelial function which leads to over-production of D-dimers. Urokinase plasminogen activator receptor (uPAR) is anchored to the cell membranes of the lung endothelial cells. As result of the activation of kallikrein, uPAR is cleaved and enters the systemic circulation as the soluble counterpart suPAR. Preliminary unpublished data from 57 Greek patients hospitalized after March 1st, 2020 in Greek hospitals due to pneumonia by confirmed SARS-CoV-2 infection showed that those with suPAR admission levels ≥ 6 ng/ml had greater risk for the development of SRF within 14 days than patients with suPAR less than 6ng/ml. The sensitivity of suPAR to detect these patients was 85.9% and the positive predictive value 85.9%. It needs to be underlined that all 21 Greek patients with suPAR≥ 6ng/ml were under treatment with hydroxychloroquine and azithromycin. These data were confirmed in 15 patients hospitalized for pneumonia by SARS-CoV-2 in Rush Medical Center at Chicago.
This prognostic ability of suPAR for unfavourable outcome is not presented for the first time; in the TRIAGE III trial that was conducted among 4,420 admissions in the emergency department in Denmark the interquartile range of suPAR was between 2.6 and 4.7 ng/ml in 30-day survivors and between 6.7 and 11.8 ng/ml in 30-day non-survivors. Previous data from the Hellenic Sepsis Study Group on 1,914 patients clearly shows a high prognostic utility of admission suPAR for 28-day mortality.
It is obvious that suPAR can early identify the start of such a type of inflammatory process in the lung parenchyma that has will soon be intensified. A recent publication has shown that this is due to the early release of interleukin-1α (IL-1α) from lung epithelial cells that are infected by the virus. This IL-1α acts as a promoting factor that stimulates the production of IL-1β and of a further cytokine storm from alveolar macrophages.
Anakinra is the only marketed product that inhibits both IL-1β and IL-1α and hence it is able to block an inflammatory response early on and to prevent the downstream inflammatory cascade. suPAR can be used as the biomarker tool to indicate patients with COVID-19 pneumonia in risk of SRF and for whom early start of anakinra may prevent development of SRF.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age equal to or above 18 years
- •Male or female gender
- •In case of women, unwillingness to remain pregnant during the study period.
- •Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent
- •Confirmed infection by SARS-CoV-2 virus using molecular techniques as defined by the World Health Organization
- •Findings in chest-X-ray or in chest computed tomography compatible with lower respiratory tract infection
- •Plasma suPAR ≥6ng/ml
排除标准
- •Age below 18 years
- •Denial for written informed consent
- •Any stage IV malignancy
- •Any do not resuscitate decision
- •Any primary immunodeficiency
- •Less than 1,500 neutrophils/mm3
- •Known hypersensitivity to anakinra
- •Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg prednisone for a greater period than the last 15 days.
- •Any anti-cytokine biological treatment the last one month
- •Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study
- •Severe hepatic failure
- •Severe renal failure
- •Any need for CPAP or mechanical ventilation
- •Any pO2/FiO2 ratio less than 150
研究组 & 干预措施
Anakinra
Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.
干预措施: Anakinra (Drug)
结局指标
主要结局
The ratio of patients who will develop serious respiratory failure (SRF)
时间窗: Visit study day 14
The primary study endpoint is the ratio of patients who will develop serious respiratory failure SRF until day 14. Patients dying before study visit of day 14 are considered achieving the primary endpoint.
次要结局
- Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7(Visit study day 1, visit study day 7)
- Comparison of the rate of patients who will develop serious respiratory failure (SRF) until day 14 with comparators from Hellenic Sepsis Study Group Database receiving standard-of-care treatment(Visit study day 14)
- Association between radiological opacities in chest computed tomography and the incidence of SRF under anakinra treatment(Visit day 14)
- Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14(Visit study day 1, visit study day 14)
- Change of SOFA score in enrolled subjects between days 1 and 7(Visit study day 1, visit study day 7)
- Change of Sequential organ failure assessment (SOFA) score in enrolled subjects between days 1 and 14(Visit study day 1, visit study day 14)
- Change of peripheral mononuclear blood cells' (PBMCs) functionality between days 1 and 7(Visit study day 1, visit study day 7)
- Change of plasma inflammatory mediators levels between days 1 and 7(Visit study day 1, visit study day 7)
- Correlation between time interval and the occurrence of SAA under treatment with anakinra(Visit day 14)
- Change of gene expression between days 1 nad 7(days 1 and 7)
- Safety of anakinra(Last patients visit, Day 90)
- Association between the time interval from hospital admission until start of anakinra and the incidence of SRF(Visit day 14)
- Rate of Mortality(Visit study day 90)
- Association of the efficacy of anakinra for subgroups of patients; the studied subgroups will be the quartiles of the respiratory ratio (pO2/FiO2) at admission; the main comorbidities; the WHO classification(Visit day 14)